SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.
External link for Salubris Biotherapeutics
45 West Watkins Mill Road
Gaithersburg, MD 20878, US
"Developing Complex Therapies to Tackle Complex Diseases" #SalubrisBio#
Samuel Murphy, CEO of Salubris Biotherapeutics, discusses the challenges of pursuing complex diseases with complex therapies, its pipeline, and how its China-based parent has provided it financial freedom from the vagaries of the capital markets. https://lnkd.in/gCTha6ms
Today we announced $35M in additional funding from Shenzhen Salubris – to advance our ongoing Phase 2 study of the first clinical-stage, selective ErbB4 agonist JK07 in Heart Failure (reduced and preserved ejection fraction), ongoing monotherapy and combination cohorts for the first IL15-CTLA4 antibody fusion JK08 in the treatment of solid tumors, and initiation of clinical development for our first-in-class biparatopic ADC JK06. We already have the first patient enrolled in RENEU-HF, our 282-subject Phase 2 study of JK07 in Heart Failure, the first patient dosed with JK08 and pembrolizumab combination treatment, and the clinical trial application for JK06 has been filed. We look forward to sharing meaningful updates on all of these clinical-stage programs later this year. https://lnkd.in/ezvK8siY
Celebrating all the remarkable SalubrisBio women! Happy International Women's Day! #salubrisbio #internationalwomensday
It is such a treat having the opportunity to work and have fun with this amazing team!
Happy Halloween from Salubris Biotherapeutics! 🎃